Keywords: amgen, buys, remaining, tularik, 3b, boost, pipeline
Amgen buys remaining 79% of Tularik for $1.3B to boost R&D pipeline
Article | 05 April 2004
Amgen, the world's leading independent biotechnology company, has reached agreement to acquire the remaining 79% of fellow California, USA-based Tularik which ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
